1. The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
2. Class II cytokine receptors and their ligands: Key antiviral and inflammatory modulators
3. Olumiant (baricitinib) prescribing information.Indianapolis (IN):Lilly;2018. URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf.
4. US Food and Drug Administration.FDA approves boxed warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz Xeljanz XR). August 2019. URL:https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐approves‐boxed‐warning‐about‐increased‐risk‐blood‐clots‐and‐death‐higher‐dose‐arthritis‐and.
5. European Medicines Agency.EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. November 2019. URL:https://www.ema.europa.eu/en/news/ema‐confirms‐xeljanz‐beused‐caution‐patients‐high‐risk‐blood‐clots#:~:text=EMA%20has%20concluded%20that%20Xeljanz high%20risk%20of%20blood%20clots.